Several drugs that combine GLP-1RA and other hormones—e.g., combined double co-agonism of GLP-1 receptors and glucagon, an analogue of oxyntomodulin, combination GLP-1/GIP or triple co-agonism of the of GLP-1/GIP/glucagon receptors—are in the pipeline for the treatment of T2D and obesity, and have been studied in the context of NAFLD/NASH [193,194,195] (Table 1 and Table 3). Here, GCGR is linked to obesity disorder.